MAPS Changes Name to Lykos Therapeutics, Raises $100 Million

<p><strong><span class&equals;"legendSpanClass"><span class&equals;"xn-location">SAN JOSE <&sol;span><&sol;span><&sol;strong>&&num;8212&semi; MAPS Public Benefit Corporation &lpar;&&num;8220&semi;MAPS PBC&&num;8221&semi;&rpar;&comma; a company dedicated to transforming mental healthcare&comma; announced an oversubscribed Series A financing and is changing its name to Lykos Therapeutics&period; MAPS PBC raised more than <span class&equals;"xn-money">&dollar;100 million<&sol;span> including conversion of previously issued convertible notes&period;<&sol;p>&NewLine;<p>The financing was led by Helena with participation from other investors&comma; including&colon; the Steven &amp&semi; Alexandra Cohen Foundation &lpar;led by <span class&equals;"xn-person">Alex Cohen<&sol;span>&rpar;&comma; Eir Therapeutics&comma; Vine Ventures&comma; True Ventures&comma; Unlikely Collaborators Foundation&comma; The Joe and Sandy Samberg Foundation&comma; Bail Capital&comma; KittyHawk Ventures and Satori Neuro&period;<&sol;p>&NewLine;<p>&&num;8220&semi;We are incredibly grateful for Helena&&num;8217&semi;s tremendous support and leadership as well as the contributions from other mission-aligned investors&comma; which comes at this critical time as we are transitioning from a development-stage company to one focused on commercialization of the potential first psychedelic-assisted therapy&comma;&&num;8221&semi; said <span class&equals;"xn-person">Amy Emerson<&sol;span>&comma; chief executive officer &lpar;&&num;8220&semi;CEO&&num;8221&semi;&rpar; of Lykos&period; &&num;8220&semi;To reflect our company evolution&comma; we selected a new name&comma; Lykos which means wolf in Greek&comma; to represent the qualities—bravery&comma; courage&comma; loyalty and intelligence—that resonate with our company&period;&&num;8221&semi;<&sol;p>&NewLine;<p>With the completion of the financing&comma; there have been changes to the Lykos board of directors&period; The new eight-member board is comprised of six Multidisciplinary Association for Psychedelic Studies &lpar;&&num;8220&semi;MAPS&&num;8221&semi;&rpar; appointees&comma; four of whom are independent directors&comma; the CEO of Lykos&comma; and <span class&equals;"xn-person">Suprotik &lpar;Protik&rpar; Basu<&sol;span> from Helena&comma; who brings over two decades of public health financing experience to the board&period;<&sol;p>&NewLine;<p>&&num;8220&semi;We are inspired by the mission and work of Lykos and honored to be chosen as their trusted partner&comma;&&num;8221&semi; said <span class&equals;"xn-person">Protik Basu<&sol;span>&comma; managing partner at Helena&period; &&num;8220&semi;This strong funding round&comma; combined with the Phase 3 results and recent new drug application submission to the FDA&comma; position Lykos to continue its journey to help transform mental health&comma; and to help address the large unmet need for the estimated 13 million Americans who suffer from PTSD<sup>1<&sol;sup>&comma; should this investigational drug used in combination with therapy be approved by the FDA&period;&&num;8221&semi;<&sol;p>&NewLine;